Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review

Area of Science:

• Hepatology
• Virology
• Transplantation Immunology

Background:

• Hepatitis C virus (HCV) infection is a primary driver of chronic liver disease, cirrhosis, and hepatocellular carcinoma, frequently necessitating liver transplantation.
• Recurrent HCV infection in liver allografts is nearly universal in viremic patients, manifesting as diverse pathologies from mild to aggressive fibrosing cholestatic hepatitis.
• Recurrent HCV post-transplant significantly accelerates allograft damage, leading to graft loss, increased morbidity, and mortality.

Purpose of the Study:

• To review current therapeutic strategies for recurrent hepatitis C virus infection in liver transplant recipients.
• To summarize recent advancements in the treatment of recurrent HCV, focusing on novel, interferon-free regimens.
• To identify and highlight emerging areas of research in recurrent HCV management.

Main Methods:

• Literature review of current and emerging therapies for recurrent HCV infection.
• Analysis of treatment outcomes, including sustained virological response rates and side effect profiles.
• Synthesis of data on the efficacy and safety of new direct-acting antiviral (DAA) regimens.

Main Results:

• Traditional HCV treatments had limited efficacy and significant side effects.
• New interferon-free therapies demonstrate high rates of sustained virological response.
• Novel treatments exhibit improved patient adherence and a more favorable safety profile compared to older regimens.

Conclusions:

• Recurrent HCV infection remains a critical challenge in liver transplantation, driving significant morbidity and mortality.
• Emerging direct-acting antiviral therapies represent a paradigm shift, offering highly effective and well-tolerated treatment options.
• Continued research is essential to optimize treatment strategies and address remaining challenges in managing post-transplant HCV.